Evidence map›Paper›PMID 41535090›Full record

ReviewRNA (New York, N.Y.)2026

Probing the epitranscriptome and RNA damage with nanopore direct RNA sequencing.

Aaron M Fleming, Cynthia J Burrows

Abstract readReview
In one paragraph

Review in RNA (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Aaron M FlemingDepartment of Chemistry, University of Utah, Salt Lake City, Utah 84112-0850, USA afleming@chem.utah.edu burrows@chem.utah.edu.ORCID 0000-0002-2000-0310
Cynthia J BurrowsDepartment of Chemistry, University of Utah, Salt Lake City, Utah 84112-0850, USA afleming@chem.utah.edu burrows@chem.utah.edu.ORCID 0000-0001-7253-8529

Funding

Chemistry and Biology of Oxidized Purine Lesions in DNAR01CA090689 · NCI · UNIVERSITY OF UTAH · PI BURROWS, CYNTHIA J, DAVID, SHEILA SUE · 2002 to 2019
$5.5M
Nanopore Detection of DNA DamageR01GM093099 · NIGMS · UNIVERSITY OF UTAH · PI BURROWS, CYNTHIA J · 2011 to 2021
$3.0M
Chemical Modifications in Regulatory Regions of DNA and RNAR35GM145237 · NIGMS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Cynthia J Burrows · 2022 to 2026
$2.3M
NCI NIH HHS R01 CA090689NIGMS NIH HHS R01 GM093099NIGMS NIH HHS R35 GM145237
6 · The paper itself

Abstract

Nanopore direct RNA sequencing (DRS) is revolutionizing our ability to analyze the epitranscriptome to evaluate nucleoside modifications in both cellular and synthetic RNA. The process involves minimal handling of fragile RNA strands, one round of reverse transcription to provide a DNA:RNA duplex, and library preparation to directly read nucleotides with their modifications as they pass through a protein nanopore embedded in a membrane. Simultaneous sequencing of hundreds of strands on a chip provides unprecedented access to whole transcriptome information. A key advantage is the long-read length that permits, for example, operon-specific epitranscriptomics of ribosomal RNA modifications as a function of cellular stress. By analyzing the entire transcriptome, the interplay of different modifications on the same RNA, or the correlation of changes in different RNAs in the same cell type, can be monitored. This review presents several recent examples of the types of experiments that are suitable for nanopore DRS as well as some of the current challenges and future expectations.

Indexed as

EpitranscriptomicsNanopore SequencingRNA DamageSequence Analysis, RNAEpitranscriptomeHumansNanoporesRNARNA, RibosomalRNARNA, Ribosomalepitranscriptomicsnanopore sequenceribosomal RNARNA modifications

Identifiers

PMID41535090
PMCPMC12990801

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.